东诚药业(002675.SZ)与北京大学、昆明植物所签署共同开发新靶点创新药物合同
格隆汇4月20日丨东诚药业(002675.SZ)公布,为进一步提升公司的核心竞争力,公司与北京大学、中国科学院昆明植物研究所三方于近期签署了《技术转让合同》和《技术开发(合作)合同》,三方共同参与研究开发新靶点抗血栓化学创新药DCP118(“DCP118”)。开发完成后,公司将获得DCP118在全球的专利、临床开发与注册、生产和市场销售的独家权利。
该产品为新靶点抗血栓候选新药,通过相关专利方法制备的新分子实体化合物,临床适应症为治疗和/或预防血栓形成性疾病。
公司通过与北京大学、中国科学院昆明植物研究所进行技术合作开发全新靶点创新药物,开拓肝素、低分子肝素类抗血栓药物之外的新领域,符合公司丰富抗血栓药物产品管线的战略定位,对公司的创新发展有积极推动作用,有助于提升公司未来的市场竞争力。此次签署技术开发合同对公司短期经营业绩不会构成重大影响,但长期来看有助于公司增加产品的经营种类,丰富产品管线,拓宽收入和利润来源,符合公司战略发展的需要。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.